INPP5D and pancreatic neoplasm: Therefore, API therapy increases SHIP-1 expression, restoring normal myelopoiesis which, in turn, reduces immunosuppressive M2-like TAM and converts them into immunogenic M1-like TAM in the TME, thus enhancing anti-tumor immune responses (i.e., CD8+ T cells) and leading to pancreatic tumor regression (Figure 8).